Physicochemical Properties
| Molecular Formula | C18H24FE2O24 |
| Molecular Weight | 736.06 |
| Exact Mass | 735.935 |
| CAS # | 8047-67-4 |
| PubChem CID | 11377634 |
| Appearance | Brown to black solid powder |
| Boiling Point | 766.4ºC at 760 mmHg |
| Melting Point | MORE THAN 51ºC |
| Flash Point | 431.2ºC |
| Hydrogen Bond Donor Count | 12 |
| Hydrogen Bond Acceptor Count | 24 |
| Rotatable Bond Count | 9 |
| Heavy Atom Count | 44 |
| Complexity | 191 |
| Defined Atom Stereocenter Count | 12 |
| SMILES | [C@H]([C@@H]([C@@H](C(=O)[O-])O)O)([C@H](C(=O)[O-])O)O.[C@H]([C@@H]([C@@H](C(=O)[O-])O)O)([C@H](C(=O)[O-])O)O.[C@H]([C@@H]([C@@H](C(=O)[O-])O)O)([C@H](C(=O)[O-])O)O.[Fe+3].[Fe+3] |
| InChi Key | ADQSUDSYBZBMFT-GFPJEPEZSA-H |
| InChi Code | InChI=1S/3C6H10O8.2Fe/c3*7-1(3(9)5(11)12)2(8)4(10)6(13)14;;/h3*1-4,7-10H,(H,11,12)(H,13,14);;/q;;;2*+3/p-6/t3*1-,2-,3-,4+;;/m000../s1 |
| Chemical Name | iron(3+);(2S,3S,4S,5R)-2,3,4,5-tetrahydroxyhexanedioate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Hemoglobin, mean corpuscular volume, serum iron, ferritin, and percent iron saturation all rise significantly after intravenous iron sucrose injection, whereas total iron binding capacity falls in tandem [1]. According to in vitro survival experiments, 40–80% of exponentially developing colon cancer cell lines (HCT116 and HT29) experienced clonal inactivation following a 2-hour exposure to 10 mM ascorbic acid. In comparison to pharmacological ascorbic acid alone, colon cancer cells treated with or without 250 µM sucrose iron showed higher amounts of labile iron after being rinsed and treated with 10 mM ascorbic acid. This led to a considerable increase in clonal cell death. 2]. through the activation of NF-κB signaling and NADPH oxidase (NOx) in human aortic endothelial cells treated with sucrose iron. Within 1 to 3 hours, HAECs produced more intracellular ROS at a concentration of 160 μg/mL due to the considerable time-dependent increase in ROS production, which lessened by 4 hours [3]. |
| ln Vivo | In subtotal nephrectomized animals, iron sucrose markedly boosted tissue superoxide generation, tissue cell adhesion molecule expression, and endothelium adhesion. In uninephrectomized ApoE-/-mice, iron sucrose exacerbates atherosclerosis in the aorta [3]. |
| References |
[1]. Intravenous Iron Sucrose for Children With Iron Deficiency Anemia. J Pediatr Hematol Oncol. 2017 Jul;39(5):e259-e262. [2]. Augmentation of Intracellular Iron Using Iron Sucrose Enhances the Toxicity of Pharmacological Ascorbate in Colon Cancer Cells. Redox Biol. 2018 Apr;14:82-87. [3]. Iron Sucrose Accelerates Early Atherogenesis by Increasing Superoxide Production and Upregulating Adhesion Molecules in CKD. J Am Soc Nephrol. 2014 Nov;25(11):2596-606. [4]. Combined Iron Sucrose and Protoporphyrin Treatment Protects Against Ischemic and Toxin-Mediated Acute Renal Failure. Kidney Int. 2016 Jul;90(1):67-76. |
| Additional Infomation | A glucaric acid-iron conjugate that is used in the treatment of IRON-DEFICIENCY ANEMIA, including in patients with chronic kidney disease, when oral iron therapy is ineffective or impractical. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~7.14 mg/mL |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.71 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 7.1 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3586 mL | 6.7929 mL | 13.5858 mL | |
| 5 mM | 0.2717 mL | 1.3586 mL | 2.7172 mL | |
| 10 mM | 0.1359 mL | 0.6793 mL | 1.3586 mL |